Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q1 2016 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, February 2016
Slide 1: Agilent Technologies Q1'16 Results Presentation
Agilent Technologies Q1’16 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenues, demand, growth opportunities, customer service and innovation plans, new product introductions, financial condition, earning
Slide 3: Agilent Results Q1'16
Agilent Results Q1’16 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q1’16 Financial Metrics Q1’16 Headlines • Revenues: $1.028B, +6.4% y/y core(1)(2),+0.2% reported (-5.3% FX, -1.0% M&A/NMR). All regions • Core growth across all businesses and grew on core bas
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Mixed core revenue growth across regions and Instrumentation and Informatics for Analytical Laboratories markets with strength in Asia, the Americas, Pharma, and Environmental/Forensics. • Operating Margin for the quarter was 21.7%(1)(2), up 210 bps ver
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory • Core revenue grew across all regions, led by Consumables and Services Asia. Broad-based portfolio strength led by GC Columns, Lab Supplies, Education, and Contract Services. • Operating Margin in the quarter was 22.1%(1)(2), up 140 bps over last
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) Pathology, Genomics, and • Continued momentum across all DGG Nucleic Acid Manufacturing Businesses: Diagnostics, Genomics, and Nucleic Acid Solutions. Highlights included Target enrichment and continued accelerating uptake for Dako Omnis reagents. • Operating Mar
Slide 7: Growth in a $45B Market – Q1'16 Results by End Market
Growth in a $45B Market – Q1’16 Results by End Market Strong core growth in Life Sciences, Dx/Clinical, and Environmental/Forensics markets partially offset by soft Chemical/Energy and Food results Analytical Laboratory End Markets Agilent Revenue by End Market (1) Q1’16 revenues: +6% y/y on core
Slide 8: Profitable Growth Plan
Agilent Profitable Growth Plan Recent Actions Delivering on “Agile Agilent” Initiatives • Multi-year program to increase efficiency and customer focus • Operating Margin up year-over-year – 4th quarter in a row • Freezing U.S. defined benefit retirement plan • I.T. streamlining initiatives on-trac
Slide 9: Strategy to Win
Agilent Strategy to Win Creating shareholder value Above Market Growth • Win enterprise lab-wide services & consumables - CrossLab • Accelerate bio-pharma penetration • Drive adoption of clinical genomics applications Aggressively expand operating margins from 18.8%(1) in FY14 to 22% by FY17 • F
Slide 10: Q2'16 and FY16 Guidance and Forward-looking Considerations
Q2’16 and FY16 Guidance and Forward-looking Considerations Based on January 29, 2016 Exchange Rates FY16 FY15 Guidance at FY16 Guidance Actual (2) mid-point (1)(2) • Revenue: $4.10B - $4.12B: growth at mid-point 4.25% core(4), 1.8% reported (1) (+0.5% NMR/M&A, -2.9% FX) Net Revenue (M$) $4,038 $4,11